ACRS
Price
$3.83
Change
+$0.02 (+0.52%)
Updated
Oct 22 closing price
Capitalization
563.77M
14 days until earnings call
Intraday BUY SELL Signals
XTNT
Price
$0.31
Change
+$0.01 (+3.33%)
Updated
Oct 22, 04:59 PM (EDT)
Capitalization
41.53M
18 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ACRS vs XTNT

ACRS vs XTNT Comparison Chart in %
View a ticker or compare two or three
VS
ACRS vs. XTNT commentary
Oct 23, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ACRS is a StrongBuy and XTNT is a Buy.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for ACRS with price predictions
Oct 22, 2026

Momentum Indicator for ACRS turns positive, indicating new upward trend

ACRS saw its Momentum Indicator move above the 0 level on October 20, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 92 similar instances where the indicator turned positive. In 80 of the 92 cases, the stock moved higher in the following days. The odds of a move higher are at 87%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where ACRS's RSI Indicator exited the oversold zone, 23 of 30 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 77%.

The Moving Average Convergence Divergence (MACD) for ACRS just turned positive on October 21, 2026. Looking at past instances where ACRS's MACD turned positive, the stock continued to rise in 35 of 43 cases over the following month. The odds of a continued upward trend are 81%.

Following a +1.59% 3-day Advance, the price is estimated to grow further. Considering data from situations where ACRS advanced for three days, in 224 of 274 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.

ACRS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ACRS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.

The Aroon Indicator for ACRS entered a downward trend on October 14, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 15 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 30 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.525) is normal, around the industry mean (2.973). P/E Ratio (-6.603) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (83.333) is also within normal values, averaging (438.009).

The Tickeron Price Growth Rating for this company is 64 (best 1 - 100 worst), indicating steady price growth. ACRS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ACRS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

A.I.Advisor
a Summary for XTNT with price predictions
Oct 22, 2026

XTNT's RSI Oscillator climbs out of oversold territory

The RSI Oscillator for XTNT moved out of oversold territory on October 20, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 30 similar instances when the indicator left oversold territory. In 27 of the 30 cases the stock moved higher. This puts the odds of a move higher at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 43 of 48 cases where XTNT's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 90%.

Following a +5.68% 3-day Advance, the price is estimated to grow further. Considering data from situations where XTNT advanced for three days, in 194 of 230 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.

XTNT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on October 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on XTNT as a result. In 74 of 91 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 81%.

The Moving Average Convergence Divergence Histogram (MACD) for XTNT turned negative on October 05, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 47 similar instances when the indicator turned negative. In 43 of the 47 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where XTNT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 83%.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 28 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.038) is normal, around the industry mean (2.874). P/E Ratio (-3.700) is within average values for comparable stocks, (2.324). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.052). Dividend Yield (0.000) settles around the average of (0.009) among similar stocks. P/S Ratio (0.426) is also within normal values, averaging (40.124).

The Tickeron Price Growth Rating for this company is 84 (best 1 - 100 worst), indicating slightly worse than average price growth. XTNT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. XTNT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

FUNDAMENTALS RATINGS
ACRS vs XTNT: Fundamental Ratings
ACRS
XTNT
OUTLOOK RATING
1..100
861
VALUATION
overvalued / fair valued / undervalued
1..100
30
Undervalued
28
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9896
PRICE GROWTH RATING
1..100
6484
P/E GROWTH RATING
1..100
1597
SEASONALITY SCORE
1..100
27n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

XTNT's Valuation (28) in the Medical Specialties industry is in the same range as ACRS (30) in the Pharmaceuticals Other industry. This means that XTNT’s stock grew similarly to ACRS’s over the last 12 months.

XTNT's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as ACRS (100) in the Pharmaceuticals Other industry. This means that XTNT’s stock grew similarly to ACRS’s over the last 12 months.

XTNT's SMR Rating (96) in the Medical Specialties industry is in the same range as ACRS (98) in the Pharmaceuticals Other industry. This means that XTNT’s stock grew similarly to ACRS’s over the last 12 months.

ACRS's Price Growth Rating (64) in the Pharmaceuticals Other industry is in the same range as XTNT (84) in the Medical Specialties industry. This means that ACRS’s stock grew similarly to XTNT’s over the last 12 months.

ACRS's P/E Growth Rating (15) in the Pharmaceuticals Other industry is significantly better than the same rating for XTNT (97) in the Medical Specialties industry. This means that ACRS’s stock grew significantly faster than XTNT’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ACRSXTNT
RSI
ODDS (%)
Bullish Trend 1 day ago
77%
Bullish Trend 1 day ago
90%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
89%
Bullish Trend 1 day ago
90%
Momentum
ODDS (%)
Bullish Trend 1 day ago
87%
Bearish Trend 1 day ago
81%
MACD
ODDS (%)
Bullish Trend 1 day ago
81%
Bearish Trend 1 day ago
90%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
83%
Bullish Trend 1 day ago
87%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
77%
Bearish Trend 1 day ago
86%
Advances
ODDS (%)
Bullish Trend 1 day ago
82%
Bullish Trend 3 days ago
84%
Declines
ODDS (%)
Bearish Trend 9 days ago
84%
Bearish Trend 7 days ago
83%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
78%
Bullish Trend 1 day ago
90%
Aroon
ODDS (%)
Bearish Trend 1 day ago
78%
N/A
COMPARISON
Comparison
Oct 23, 2026
Stock price -- (ACRS: $3.81 vs. XTNT: $0.30)
Brand notoriety: ACRS and XTNT are both not notable
ACRS represents the Biotechnology, while XTNT is part of the Medical/Nursing Services industry
Current volume relative to the 65-day Moving Average: ACRS: 84% vs. XTNT: 6%
Market capitalization -- ACRS: $563.77M vs. XTNT: $41.53M
ACRS [@Biotechnology] is valued at $563.77M. XTNT’s [@Medical/Nursing Services] market capitalization is $41.53M. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $135.64B. The market cap for tickers in the [@Medical/Nursing Services] industry ranges from $837 to $173.92B. The average market capitalization across the [@Biotechnology] industry is $2.18B. The average market capitalization across the [@Medical/Nursing Services] industry is $5.76B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ACRS’s FA Score shows that 1 FA rating(s) are green while XTNT’s FA Score has 1 green FA rating(s).

  • ACRS’s FA Score: 1 green, 4 red.
  • XTNT’s FA Score: 1 green, 4 red.
According to our system of comparison, ACRS is a better buy in the long-term than XTNT.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ACRS’s TA Score shows that 6 TA indicator(s) are bullish while XTNT’s TA Score has 4 bullish TA indicator(s).

  • ACRS’s TA Score: 6 bullish, 2 bearish.
  • XTNT’s TA Score: 4 bullish, 3 bearish.
According to our system of comparison, ACRS is a better buy in the short-term than XTNT.

Price Growth

ACRS (@Biotechnology) experienced а +12.72% price change this week, while XTNT (@Medical/Nursing Services) price change was -7.06% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.10%. For the same industry, the average monthly price growth was -18.18%, and the average quarterly price growth was -15.20%.

The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -1.62%. For the same industry, the average monthly price growth was -10.72%, and the average quarterly price growth was -10.29%.

Reported Earning Dates

ACRS is expected to report earnings on Nov 05, 2026.

XTNT is expected to report earnings on Nov 09, 2026.

Industries' Descriptions

@Biotechnology (-1.10% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

@Medical/Nursing Services (-1.62% weekly)

The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.

View a ticker or compare two or three
ACRS
Daily Signal:
Gain/Loss:
XTNT
Daily Signal:
Gain/Loss:
Interact to see
Advertisement

ACRS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ACRS has been loosely correlated with CRVS. These tickers have moved in lockstep 64% of the time. This A.I.-generated data suggests there is some statistical probability that if ACRS jumps, then CRVS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ACRS
1D Price
Change %
ACRS100%
+0.52%
CRVS - ACRS
64%
Loosely correlated
+5.97%
STRRP - ACRS
52%
Loosely correlated
+3.16%
QUCY - ACRS
40%
Loosely correlated
N/A
UFPT - ACRS
39%
Loosely correlated
+2.49%
IMNM - ACRS
38%
Loosely correlated
+1.44%
More

XTNT and

Correlation & Price change

A.I.dvisor tells us that XTNT and STRRP have been poorly correlated (+31% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that XTNT and STRRP's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To XTNT
1D Price
Change %
XTNT100%
+5.41%
STRRP - XTNT
31%
Poorly correlated
+3.16%
CVRX - XTNT
26%
Poorly correlated
N/A
ACRS - XTNT
25%
Poorly correlated
+0.52%
MBOT - XTNT
24%
Poorly correlated
+0.19%
OM - XTNT
24%
Poorly correlated
+2.96%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
XRTX0.970.04
+4.16%
XORTX Therapeutics Inc.
UHAL56.801.04
+1.87%
U-Haul Holding Company
PONY5.02-0.02
-0.40%
Pony AI Inc
ALIS8.18-0.18
-2.15%
Calisa Acquisition Corp
WYFI10.55-1.11
-9.52%
WhiteFiber Inc